A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis

Journal of Hepatology

Volumn 54, Issue 5, 2011, Pages 1011-1019

  Ratziu, Vlad ^a   De Ledinghen, Victor ^b   Oberti, Fréderic ^c   Mathurin, Philippe ^d   Wartelle Bladou, Claire ^e   Renou, Christophe ^f   Sogni, Philippe ^g   Maynard, Marianne ^h   Larrey, Dominique ⁱ   Serfaty, Lawrence ^j   Bonnefont Rousselot, Dominique ^k,l   Bastard, Jean Philippe ^m   Riviére, Marc ⁿ   Spénard, Jean ^n,o  

^a SORBONNE UNIVERSITÉ   (France)

^b HAUT LÉVÊQUE HOSPITAL   (France)

^c ANGERS UNIVERSITY HOSPITAL   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e Hematology Oncology Day Hospital   (France)

^f CHG d'Hèyres   (France)

^g Hôpital Cochin ^*  (France)

^h HÔTEL DIEU   (France)

ⁱ MONTPELLIER UNIVERSITY HOSPITAL   (France)

^j HÔPITAL SAINT ANTOINE   (France)

^k PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^l UNIVERSITÉ PARIS DESCARTES   (France)

^m HÔPITAL TENON   (France)

ⁿ Axcan Pharma Inc   (Canada)

^o UNIVERSITÉ DE MONTRÉAL   (Canada)

more..

Author keywords

Aminotransferases; Fibrosis; Insulin resistance; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Randomized clinical trials; Steatosis

Indexed keywords

ALANINE AMINOTRANSFERASE; PLACEBO; URSODEOXYCHOLIC ACID;

ABDOMINAL CRAMP; ABDOMINAL DISCOMFORT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASTHENIA; BACKACHE; CONTROLLED STUDY; DEATH; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FIBROSIS; FLATULENCE; GLYCEMIC CONTROL; HEPATITIS; HUMAN; INSULIN RESISTANCE; LIVER CARCINOGENESIS; LIVER CIRRHOSIS; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; METABOLISM; MULTICENTER STUDY; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; WEIGHT CHANGE;

EID: 79954764140     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.08.030     Document Type: Article

References (59)

1. L.A. Adams, J.F. Lymp, J. St. Sauver, S.O. Sanderson, K.D. Lindor, and A. Feldstein The natural history of nonalcoholic fatty liver disease: a population-based cohort study Gastroenterology 129 1 2005 113 121 (Pubitemid 41002048)
2. P. Angulo, E.R. Dickson, T.M. Therneau, R.A. Jorgensen, C. Smith, and C.K. DeSotel Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial J Hepatol 30 5 1999 830 835 (Pubitemid 29248983)
3. P. Angulo, J.M. Hui, G. Marchesini, E. Bugianesi, J. George, and G.C. Farrell The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD Hepatology 45 4 2007 846 854 (Pubitemid 46631552)
4. M.L. Balmerm, K. Siegrist, A. Zimmermann, and J.F. Dufour Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis Liver Int 29 2009 1184 1188
5. S. Bellentani, Y.C. Chao, I. Ferretti, R. Panini, and C. Tiribelli Chronic administration of ursodeoxycholic and tauroursodeoxycholic acid changes microsomal membrane lipid content and fatty acid compositions in rats Biochem Biophys Res Commun 220 3 1996 479 483 (Pubitemid 26198539)
6. C. Bernstein, C.M. Payne, H. Bernstein, and H. Garewal Activation of the metallothionein IIA promoter and other key stress response elements by ursodeoxycholate in HepG2 cells: relevance to the cytoprotective function of ursodeoxycholate Pharmacology 65 2002 2 9 (Pubitemid 34233913)
7. S.H. Caldwell, and D.M. Crespo The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease J Hepatol 40 4 2004 578 584 (Pubitemid 38367778)
8. P. Cales, F. Laine, J. Boursier, Y. Deugnier, V. Moal, and F. Oberti Comparison of blood tests for liver fibrosis specific or not to NAFLD J Hepatol 50 1 2009 165 173
9. C. Colombo, A. Crosignani, M. Assaisso, P.M. Battezzati, M. Podda, and A. Giunta Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study Hepatology 16 4 1992 924 930
10. S.N. Cullen, C. Rust, K. Fleming, C. Edwards, U. Beuers, and R.W. Chapman High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective J Hepatol 48 5 2008 792 800
11. J.F. Dufour, C.M. Oneta, J.J. Gonvers, F. Bihl, A. Cerny, and J.M. Cereda Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis Clin Gastroenterol Hepatol 4 2006 1537 1543 (Pubitemid 44880031)
12. M. Ekstedt, L.E. Franzen, U.L. Mathiesen, L. Thorelius, M. Holmqvist, and G. Bodemar Long-term follow-up of patients with NAFLD and elevated liver enzymes Hepatology 44 4 2006 865 873 (Pubitemid 46489550)
13. G.C. Farrell, and C.Z. Larter Nonalcoholic fatty liver disease: from steatosis to cirrhosis Hepatology 43 2 Suppl. 1 2006 S99 S112
14. A.E. Feldstein, A. Canbay, P. Angulo, M. Taniai, L.J. Burgart, and K.D. Lindor Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis Gastroenterology 125 2 2003 437 443 (Pubitemid 36929425)
15. I.N. Guha, J. Parkes, P. Roderick, D. Chattopadhyay, R. Cross, and S. Harris Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers Hepatology 47 2 2008 455 460 (Pubitemid 351280713)
16. D.M. Harnois, P. Angulo, R.A. Jorgensen, N.F. Larusso, and K.D. Lindor High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis Am J Gastroenterol 96 5 2001 1558 1562 (Pubitemid 32455090)
17. G.S. Hotamisligil, D.L. Murray, L.N. Choy, and B.M. Spiegelman Tumor necrosis factor alpha inhibits signaling from the insulin receptor Proc Natl Acad Sci USA 91 11 1994 4854 4858 (Pubitemid 24177748)
18. T. Ikegami, Y. Matsuzaki, S. Fukushima, J. Shoda, J.L. Olivier, and B. Bouscarel Suppressive effect of ursodeoxycholic acid on type IIA phospholipase A2 expression in HepG2 cells Hepatology 41 4 2005 896 905 (Pubitemid 40467587)
19. P. Jepsen, H. Vilstrup, L. Mellemkjaer, A.M. Thulstrup, J.H. Olsen, and J.A. Baron Prognosis of patients with a diagnosis of fatty liver - a registry-based cohort study Hepatogastroenterology 50 54 2003 2101 2104 (Pubitemid 37468003)
20. M.B. Katan Weight-loss diets for the prevention and treatment of obesity N Engl J Med 360 9 2009 923 925
21. Y. Kawamata, R. Fujii, M. Hosoya, M. Harada, H. Yoshida, and M. Miwa A G protein-coupled receptor responsive to bile acids J Biol Chem 278 11 2003 9435 9440 (Pubitemid 36800434)
22. D.E. Kleiner, E.M. Brunt, M. Van Natta, C. Behling, M.J. Contos, and O.W. Cummings Design and validation of a histological scoring system for nonalcoholic fatty liver disease Hepatology 41 2005 1313 1321 (Pubitemid 40770284)
23. G.E. Kobak, G. Deutsch, and R. Dahl Fat-laden hepatocytes are more prone to cellular necrosis than apoptosis when exposed to hydrophobic bile acids Gastroenterology 122 Suppl. 2002 A642
24. D. Lapenna, G. Ciofani, D. Festi, M. Neri, S.D. Pierdomenico, and M.A. Giamberardino Antioxidant properties of ursodeoxycholic acid Biochem Pharmacol 64 2002 1661 1667 (Pubitemid 35333426)
25. J. Laurin, K.D. Lindor, J.S. Crippin, A. Gossard, G.J. Gores, and J. Ludwig Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study Hepatology 23 1996 1464 1467
26. U. Leuschner, B. Lindenthal, G. Herrman, J.C. Arnold, M. Rossle, and H.-J. Cordes High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial Hepatology 52 2010 472 479
27. K.D. Lindor, K.V. Kowdley, E.J. Heathcote, M.E. Harrison, R. Jorgensen, and P. Angulo Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial Hepatology 39 2004 770 778 (Pubitemid 38337657)
28. K.D. Lindor, K.V. Kowdley, V.A. Luketic, M.E. Harrison, T. McCashland, and A.S. Befeler High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis Hepatology 50 3 2009 808 814
29. P. Ljubuncic, B. Fuhrman, J. Oiknine, M. Aviram, and A. Bomzon Effect of deoxycholic acid and ursodeoxycholic acid on lipid peroxidation in cultured macrophages Gut 39 1996 475 478 (Pubitemid 26338541)
30. M. Makishima, A.Y. Okamoto, J.J. Repa, H. Tu, R.M. Learned, and A. Luk Identification of a nuclear receptor for bile acids Science 284 5418 1999 1362 1365 (Pubitemid 29289663)
31. S.A. Mitchell, D.S. Bansi, N. Hunt, K. Von Bergmann, K.A. Fleming, and R.W. Chapman A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis Gastroenterology 121 4 2001 900 907 (Pubitemid 32959399)
32. M. Neuman, P. Angulo, I. Malkiewicz, R. Jorgensen, N. Shear, and E.R. Dickson Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis J Gastroenterol Hepatol 17 2002
33. Y. Nishigaki, H. Ohnishi, H. Moriwaki, and Y. Muto Ursodeoxycholic acid corrects defective natural killer activity by inhibiting prostaglandin E2 production in primary biliary cirrhosis Dig Dis Sci 41 1996 1487 1493 (Pubitemid 26245933)
34. U. Ozcan, E. Yilmaz, L. Ozcan, M. Furuhashi, E. Vaillancourt, and R.O. Smith Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes Science 313 5790 2006 1137 1140 (Pubitemid 44300242)
35. D.J. Parks, S.G. Blanchard, R.K. Bledsoe, G. Chandra, T.G. Consler, and S.A. Kliewer Bile acids: natural ligands for an orphan nuclear receptor Science 284 5418 1999 1365 1368 (Pubitemid 29289664)
36. G. Pelletier, D. Roulot, T. Davion, C. Masliah, X. Causse, and F. Oberti A randomized controlled trial of ursodeoxycholic acid in patients with alcohol-induced cirrhosis and jaundice Hepatology 37 4 2003 887 892 (Pubitemid 36397400)
37. M.J. Perez, and O. Briz Bile-acid-induced cell injury and protection World J Gastroenterol 15 2009 1677 1689
38. T. Poynard, F. Imbert-Bismut, V. Ratziu, S. Chevret, C. Jardel, and J. Moussalli Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial J Viral Hepat 9 2 2002 128 133 (Pubitemid 36002476)
39. T. Poynard, J. McHutchison, M. Manns, R.P. Myers, and J. Albrecht Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin Hepatology 38 2 2003 481 492 (Pubitemid 36919870)
40. T. Poynard, Y. Ngo, P. Marcellin, S. Hadziyannis, V. Ratziu, and Y. Benhamou Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus J Viral Hepat 16 3 2009 203 213
41. T. Poynard, F. Zoulim, V. Ratziu, F. Degos, F. Imbert-Bismut, and P. Deny Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection Am J Gastroenterol 100 9 2005 1970 1980
42. L. Qiao, A. Yacoub, E. Studer, S. Gupta, X.Y. Pei, and S. Grant Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes Hepatology 35 2002 779 789 (Pubitemid 34258371)
43. V. Ratziu, M. Chojkier, M. Sheikh, A.J. Sanyal, J.K. Lim, and H.S. Conjeevaram Safety, tolerability and preliminary activity of GS-9450, a selective caspase inhibitor, in patients with nonalcoholic steatohepatitis J Hepatol 52 2010 S38
44. V. Ratziu, P. Giral, S. Jacqueminet, F. Charlotte, A. Hartemann-Heurtier, and L. Serfaty Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial Gastroenterology 135 1 2008 100 110 (Pubitemid 351916703)
45. V. Ratziu, J. Massard, F. Charlotte, D. Messous, F. Imbert-Bismut, and L. Bonyhay Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease BMC Gastroenterol 6 2006 6
46. V. Ratziu, and T. Poynard Assessing the outcome of nonalcoholic steatohepatitis? It's time to get serious Hepatology 44 4 2006 802 805 (Pubitemid 46489542)
47. C.M. Rodrigues, G. Fan, X. Ma, B.T. Kren, and C.J. Steer A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation J Clin Invest 101 1998 2790 2799 (Pubitemid 28294588)
48. C.M. Rodrigues, G. Fan, P.Y. Wong, B.T. Kren, and C.J. Steer Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production Mol Med 4 3 1998 165 178 (Pubitemid 28223968)
49. D. Rost, G. Rudolph, P. Kloeters-Plachky, and A. Stiehl Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis Hepatology 40 3 2004 693 698 (Pubitemid 39265592)
50. H. Sato, A. Macchiarulo, C. Thomas, A. Gioiello, M. Une, and A.F. Hofmann Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies J Med Chem 51 6 2008 1831 1841 (Pubitemid 351438866)
51. T.C. Schreuder, B.J. Verwer, C.M. van Nieuwkerk, and C.J. Mulder Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment World J Gastroenterol 14 2008 2474 2486 (Pubitemid 352037734)
52. S.J. Schwarzenberg, and M. Bundy Ursodeoxycholic acid modifies gut-derived endotoxemia in neonatal rats Pediatr Res 35 1994 214 217 (Pubitemid 24039151)
53. C. Soderberg, P. Stal, J. Askling, H. Glaumann, G. Lindberg, and J. Marmur Decreased survival of subjects with elevated liver function tests during a 28-year follow-up Hepatology 51 2 2010 595 602
54. A. Suzuki, J. Lymp, J.S. Sauver, P. Angulo, and K. Lindor Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis Liver Int 26 10 2006 1209 1216 (Pubitemid 44741208)
55. K.T. Uysal, S.M. Wiesbrock, M.W. Marino, and G.S. Hotamisligil Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function Nature 389 6651 1997 610 614 (Pubitemid 27446179)
56. P.C. van de Meeberg, R.H. Houwen, M. Sinaasappel, H.G. Heijerman, C.M. Bijleveld, and G.P. Vanberge-Henegouwen Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis-related cholestatic liver disease. Results of a randomized study with 1-year follow-up Scand J Gastroenterol 32 4 1997 369 373 (Pubitemid 27156175)
57. M. Watanabe, S.M. Houten, L. Wang, A. Moschetta, D.J. Mangelsdorf, and R.A. Heyman Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c J Clin Invest 113 10 2004 1408 1418 (Pubitemid 39071696)
58. S.R. Weston, W. Leyden, R. Murphy, N.M. Bass, B.P. Bell, and M.M. Manos Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease Hepatology 41 2 2005 372 379 (Pubitemid 40165382)
59. Q. Xie, V.I. Khaoustov, C.C. Chung, J. Sohn, B. Krishnan, and D.E. Lewis Effect of tauroursodeoxycholic acid on endoplasmic reticulum stress-induced caspase-12 activation Hepatology 36 3 2002 592 601 (Pubitemid 34977169)